Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
The change in the total score of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) from the beginning to the end of the double-blind treatment period or to the last post-randomization assessment.
The investigator's Clinical Global Impression of the Severity (CGI-S) of schizophrenia and rating of mental function on a Personal and Social Performance Scale (PSP). Evaluations of adverse events, laboratory tests, and other measures of drug safety.
18 Years and older (Adult, Senior)
September 21, 2005
June 8, 2011
† Study has passed its completion date and status has not been verified in more than two years.